• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SCORE2-OP 风险预测算法:估计四个地理风险地区老年人的新发心血管事件风险。

SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.

出版信息

Eur Heart J. 2021 Jul 1;42(25):2455-2467. doi: 10.1093/eurheartj/ehab312.

DOI:10.1093/eurheartj/ehab312
PMID:34120185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8248997/
Abstract

AIMS

The aim of this study was to derive and validate the SCORE2-Older Persons (SCORE2-OP) risk model to estimate 5- and 10-year risk of cardiovascular disease (CVD) in individuals aged over 70 years in four geographical risk regions.

METHODS AND RESULTS

Sex-specific competing risk-adjusted models for estimating CVD risk (CVD mortality, myocardial infarction, or stroke) were derived in individuals aged over 65 without pre-existing atherosclerotic CVD from the Cohort of Norway (28 503 individuals, 10 089 CVD events). Models included age, smoking status, diabetes, systolic blood pressure, and total- and high-density lipoprotein cholesterol. Four geographical risk regions were defined based on country-specific CVD mortality rates. Models were recalibrated to each region using region-specific estimated CVD incidence rates and risk factor distributions. For external validation, we analysed data from 6 additional study populations {338 615 individuals, 33 219 CVD validation cohorts, C-indices ranged between 0.63 [95% confidence interval (CI) 0.61-0.65] and 0.67 (0.64-0.69)}. Regional calibration of expected-vs.-observed risks was satisfactory. For given risk factor profiles, there was substantial variation across the four risk regions in the estimated 10-year CVD event risk.

CONCLUSIONS

The competing risk-adjusted SCORE2-OP model was derived, recalibrated, and externally validated to estimate 5- and 10-year CVD risk in older adults (aged 70 years or older) in four geographical risk regions. These models can be used for communicating the risk of CVD and potential benefit from risk factor treatment and may facilitate shared decision-making between clinicians and patients in CVD risk management in older persons.

摘要

目的

本研究旨在推导和验证 SCORE2-老年人(SCORE2-OP)风险模型,以估计四个地理风险区域中 70 岁以上个体的 5 年和 10 年心血管疾病(CVD)风险。

方法和结果

在没有预先存在的动脉粥样硬化性 CVD 的 65 岁以上个体中,使用挪威队列(28503 名个体,10089 例 CVD 事件),通过竞争风险调整模型来估计 CVD 风险(CVD 死亡率、心肌梗死或中风)。模型包括年龄、吸烟状况、糖尿病、收缩压以及总胆固醇和高密度脂蛋白胆固醇。根据国家特异性 CVD 死亡率定义了四个地理风险区域。使用特定区域的估计 CVD 发病率和风险因素分布,对每个区域的模型进行重新校准。为了外部验证,我们分析了来自 6 个额外研究人群的数据{338615 名个体,33219 例 CVD 验证队列,C 指数在 0.63 [95%置信区间(CI)0.61-0.65]和 0.67(0.64-0.69)之间}。预期与观察到的风险的区域校准令人满意。对于给定的风险因素谱,在四个风险区域中,估计的 10 年 CVD 事件风险存在很大差异。

结论

推导、重新校准并外部验证了竞争风险调整的 SCORE2-OP 模型,以估计四个地理风险区域中 70 岁及以上老年人的 5 年和 10 年 CVD 风险。这些模型可用于交流 CVD 风险以及通过风险因素治疗获得的潜在益处,并可能促进临床医生和患者在老年人 CVD 风险管理方面的共同决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484f/8248997/271f4ab8d4db/ehab312f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484f/8248997/271f4ab8d4db/ehab312f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484f/8248997/271f4ab8d4db/ehab312f6.jpg

相似文献

1
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.SCORE2-OP 风险预测算法:估计四个地理风险地区老年人的新发心血管事件风险。
Eur Heart J. 2021 Jul 1;42(25):2455-2467. doi: 10.1093/eurheartj/ehab312.
2
Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model.亚太地区心血管疾病的风险预测:SCORE2亚太模型
Eur Heart J. 2025 Feb 21;46(8):702-715. doi: 10.1093/eurheartj/ehae609.
3
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.SCORE2 风险预测算法:用于评估欧洲人群 10 年心血管疾病风险的新模型。
Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309.
4
Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort.系统性冠状动脉风险评估 2 (SCORE2)和 SCORE2-老年人在 EPIC-Norfolk 前瞻性人群队列中的验证。
Eur J Prev Cardiol. 2024 Jan 25;31(2):182-189. doi: 10.1093/eurjpc/zwad318.
5
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.SCORE2-Diabetes:欧洲 2 型糖尿病的 10 年心血管风险评估。
Eur Heart J. 2023 Jul 21;44(28):2544-2556. doi: 10.1093/eurheartj/ehad260.
6
Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.个体终生心血管风险预测及潜在治疗获益:LIFE-CVD2 模型在四个欧洲风险地区的开发和重新校准。
Eur J Prev Cardiol. 2024 Oct 10;31(14):1690-1699. doi: 10.1093/eurjpc/zwae174.
7
Systematic Coronary Risk Evaluation 2 for Older Persons: 10 years risk validation, clinical utility, and potential improvement.老年人系统性冠状动脉风险评估2:10年风险验证、临床效用及潜在改进
Eur J Prev Cardiol. 2025 May 12;32(7):527-536. doi: 10.1093/eurjpc/zwae383.
8
Predicting cardiovascular morbidity and mortality with SCORE2 (OP) and Framingham risk estimates in combination with indicators of biological ageing.结合生物学衰老指标,用SCORE2(OP)和弗雷明汉姆风险评估预测心血管疾病的发病率和死亡率。
Age Ageing. 2025 Mar 28;54(4). doi: 10.1093/ageing/afaf075.
9
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2.提高表面健康人群的 10 年心血管风险预测:在 SCORE2 基础上灵活添加风险修正因子。
Eur J Prev Cardiol. 2023 Oct 26;30(15):1705-1714. doi: 10.1093/eurjpc/zwad187.
10
Performance of SCORE2 and SCORE2-OP risk algorithms in a Cypriot cohort.塞浦路斯队列中 SCORE2 和 SCORE2-OP 风险算法的性能。
Int Angiol. 2022 Dec;41(6):492-499. doi: 10.23736/S0392-9590.22.04958-6. Epub 2022 Oct 26.

引用本文的文献

1
Cardiovascular Risk Prediction in Older Adults.老年人的心血管风险预测
Curr Atheroscler Rep. 2025 Sep 9;27(1):88. doi: 10.1007/s11883-025-01339-2.
2
Assessing the prevalence of non-communicable diseases and their modifiable risk factors in primary healthcare: retrospective analysis of annual health screening in the United Arab Emirates.评估初级医疗保健中慢性病及其可改变风险因素的患病率:阿联酋年度健康筛查的回顾性分析
BMJ Open. 2025 Aug 22;15(8):e098231. doi: 10.1136/bmjopen-2024-098231.
3
Point-of-care testing of cardiovascular risk factors in Viennese community pharmacies: A cross-sectional study.

本文引用的文献

1
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.SCORE2 风险预测算法:用于评估欧洲人群 10 年心血管疾病风险的新模型。
Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309.
2
Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment.考虑未来开始使用他汀类药物治疗的情况下预测心血管疾病风险。
Am J Epidemiol. 2021 Oct 1;190(10):2000-2014. doi: 10.1093/aje/kwab031.
3
Validation of the cardiovascular risk model NORRISK 2 in South Asians and people with diabetes.
维也纳社区药房心血管危险因素的即时检测:一项横断面研究。
Prev Med Rep. 2025 Aug 10;57:103209. doi: 10.1016/j.pmedr.2025.103209. eCollection 2025 Sep.
4
Saudi Heart Association Position Statement on Troponin use for Cardiovascular Risk Screening in Asymptomatic Populations.沙特心脏协会关于肌钙蛋白用于无症状人群心血管风险筛查的立场声明。
J Saudi Heart Assoc. 2025 Jul 16;37(3):10. doi: 10.37616/2212-5043.1444. eCollection 2025.
5
Improving cardiovascular risk stratification: the role of abdominal obesity in predicting MACEs.改善心血管风险分层:腹型肥胖在预测主要不良心血管事件中的作用。
Cardiovasc Diabetol. 2025 Aug 11;24(1):328. doi: 10.1186/s12933-025-02885-4.
6
Glycaemic control, low levels of high-density lipoprotein, and high cardiovascular risk are associated with cardiovascular autonomic neuropathy.血糖控制不佳、高密度脂蛋白水平低以及心血管风险高与心血管自主神经病变相关。
Diabetol Metab Syndr. 2025 Aug 4;17(1):313. doi: 10.1186/s13098-025-01834-1.
7
Applicability and Risk Stratification of QRISK®, Framingham Risk Score, Systematic Coronary Risk Evaluation (SCORE), and American College of Cardiology/American Heart Association (ACC/AHA) Risk Assessment Tools Among Patients in Taif, Saudi Arabia.QRISK®、弗雷明汉风险评分、系统性冠状动脉风险评估(SCORE)以及美国心脏病学会/美国心脏协会(ACC/AHA)风险评估工具在沙特阿拉伯塔伊夫患者中的适用性及风险分层
Cureus. 2025 Jun 28;17(6):e86910. doi: 10.7759/cureus.86910. eCollection 2025 Jun.
8
Deep learning can predict cardiovascular events from liver imaging.深度学习可通过肝脏成像预测心血管事件。
JHEP Rep. 2025 Apr 22;7(8):101427. doi: 10.1016/j.jhepr.2025.101427. eCollection 2025 Aug.
9
Association Between ECG Findings and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score: A Cross-Sectional Analysis of a Cohort Study.心电图结果与动脉粥样硬化性心血管疾病(ASCVD)风险评分之间的关联:一项队列研究的横断面分析
Health Sci Rep. 2025 Jul 9;8(7):e71026. doi: 10.1002/hsr2.71026. eCollection 2025 Jul.
10
A simple score, CKMS-BAG, to predict cardiovascular risk with cardiovascular-kidney-metabolic health metrics.一种简单的评分系统CKMS-BAG,用于通过心血管-肾脏-代谢健康指标预测心血管风险。
iScience. 2025 May 30;28(7):112780. doi: 10.1016/j.isci.2025.112780. eCollection 2025 Jul 18.
验证心血管风险模型 NORRISK 2 在南亚人群和糖尿病患者中的适用性。
Scand Cardiovasc J. 2021 Feb;55(1):56-62. doi: 10.1080/14017431.2020.1821909. Epub 2020 Oct 19.
4
The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults.美国老年人心血管合并队列风险评估的准确性
J Gen Intern Med. 2020 Jun;35(6):1701-1708. doi: 10.1007/s11606-019-05361-4. Epub 2019 Oct 30.
5
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions.世界卫生组织心血管疾病风险图表:修订后的模型可估算 21 个全球区域的风险。
Lancet Glob Health. 2019 Oct;7(10):e1332-e1345. doi: 10.1016/S2214-109X(19)30318-3. Epub 2019 Sep 2.
6
Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.预测胆固醇降低、血压降低、抗血栓治疗和戒烟对明显健康人群的个体化终生获益。
Eur Heart J. 2020 Mar 14;41(11):1190-1199. doi: 10.1093/eurheartj/ehz239.
7
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.他汀类药物治疗老年人的疗效和安全性:28 项随机对照试验个体参与者数据的荟萃分析。
Lancet. 2019 Feb 2;393(10170):407-415. doi: 10.1016/S0140-6736(18)31942-1.
8
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.PROBAST:一种用于评估偏倚风险和预测模型研究适用性的工具。
Ann Intern Med. 2019 Jan 1;170(1):51-58. doi: 10.7326/M18-1376.
9
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.个体化循证医学:预测异质性治疗效果的方法。
BMJ. 2018 Dec 10;363:k4245. doi: 10.1136/bmj.k4245.
10
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies.四项心血管风险算法经系统重新校准后的均衡:86 项前瞻性研究的个体参与者荟萃分析。
Eur Heart J. 2019 Feb 14;40(7):621-631. doi: 10.1093/eurheartj/ehy653.